Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

10 May 2016 - 16 May 2016
11 May 2016 - 13 May 2016

Pill Appearance Key to Patient Compliance

By BiotechDaily International staff writers
Posted on 31 Jul 2014
Print article
Heart attack patients are 30% more likely to discontinue generic cardiovascular medications if their pills change in color or shape, according to a new study.

Researchers at Brigham and Women's Hospital (Boston, MA, USA) conducted cohort and nested case–control studies to determine whether nonpersistent use of generic drugs among 11,513 patients with cardiovascular disease (CVD) after myocardial infarction (MI) is associated with inconsistent appearance of their medications. Study patients were those who discontinued their index medication for at least one month, while control patients continued treatment uninterrupted. Rates of changes in pill color and shape during the year after MI were calculated, and the odds of discordance among case and control patients were compared.

The results showed that 29% of the patients had a change in pill shape or color during the study, correlating with a total of 4, 573 episodes of non-persistence. Statins had the most changes in appearance, whereas β-blockers had the fewest. The researchers found that the odds of nonpersistence in case patients increased by 34% after a change in pill color and 66% after a change in pill shape. Further adjusting the odds ratios for pharmacy changes or use of a mail-order pharmacy did not change the statistically significant associations with nonpersistence, except for color alone. The study was published on July 14, 2014, in Annals of Internal Medicine.

“Some pharmacies do alert patients to changes in medication appearance by placing a sticker on the container. But pill bottles can have so many stickers that the message might be missed,” said lead author Aaron Kesselheim, MD. “Patients need to know that it's common for generics to change their appearance, and that doesn't mean they're working any differently. If patients are concerned by a shift in their medication's shape or color, they should call their doctor or pharmacist rather than just abandoning the drug—even for a short time.”

Currently, the US Food and Drug Administration (FDA) do not interfere with the visual appearance of drugs, which are considered a form of intellectual property. However, the US Supreme Court ruled in 1995 that if the color of a medical pill served a specific function, then competitors were allowed to copy it.

Related Links:

Brigham and Women's Hospital



Print article

Channels

Genomics/Proteomics

view channel
Image: A confocal microscopy image of human fibroblasts derived from embryonic stem cells. The nuclei appear in blue, while smaller and more numerous mitochondria appear in red (Photo courtesy of Dr. Shoukhrat Mitalipov, Oregon Health & Science University).

Stem Cells Derived from Older Individuals May Carry Unsafe Mitochondrial DNA Mutations

Induced pluripotent stem cells (iPSCs) derived from the skin fibroblasts of older individuals have a likelihood of harboring mitochondrial DNA mutations, which may render them unfit for clinical applications.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

DNA Synthesis Specialists Acquire Advanced Software Design Capabilities

An American biotech firm that develops and produces synthetic DNA has established an international presence by purchasing an Israeli genetic design software company. Twist Bioscience Corporation (San Francisco, CA, USA), a company specializing in rapid, high-quality DNA synthesis, announced that Genome Compiler Corporation... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.